Whole-Cell Vaccine Preparation Through Prussian Blue Nanoparticles-Elicited Immunogenic Cell Death and Loading in Gel Microneedles Patches
Related Experiment Video
Updated: Apr 28, 2026
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
Published on: April 29, 2015
Wenxin Fu1,2, Qianqian Li1,2, Jingyi Sheng2
1State Key Laboratory of Digital Medical Engineering, Basic Medicine Research and Innovation Center of Ministry of Education, Southeast University, Nanjing 211102, China.
Abstract:
Tumor whole-cell vaccines are designed to introduce a wide range of tumor-associated antigens into the body to counteract the immunosuppression caused by tumors. In cases of lymphoma of which the specific antigen is not yet determined, the tumor whole-cell vaccine offers distinct advantages. However, there is still a lack of research on an effective preparation method for the lymphoma whole-cell vaccine. To solve this challenge, we prepared a whole-cell vaccine derived from non-Hodgkin B-cell lymphoma (A20) via the photothermal effect mediated by Prussian blue nanoparticles (PBNPs). The immune activation effect of this vaccine against lymphoma was verified at the cellular level. The PBNPs-treated A20 cells underwent immunogenic cell death (ICD), causing the loss of their ability to form tumors while retaining their ability to trigger an immune response. A20 cells that experienced ICD were further ultrasonically crushed to prepare the A20 whole-cell vaccine with exposed antigens and enhanced immunogenicity. The A20 whole-cell vaccine was able to activate the dendritic cells (DCs) to present antigens to T cells and trigger specific immune responses against lymphoma. Whole-cell vaccines are primarily administered through direct injection, a method that often results in low delivery efficiency and poor patient compliance. Comparatively, the microneedle patch system provides intradermal delivery, offering enhanced lymphatic absorption and improved patient adherence due to its minimally invasive approach. Thus, we developed a porous microneedle patch system for whole-cell vaccine delivery using Gelatin Methacryloyl (GelMA) hydrogel and n-arm-poly(lactic-co-glycolic acid) (n-arm-PLGA). This whole-cell vaccine combined with porous gel microneedle patch delivery system has the potential to become a simple immunotherapy method with controllable production and represents a promising new direction for the treatment of lymphoma.
Insights
Researchers developed a novel lymphoma whole-cell vaccine using Prussian blue nanoparticles and a microneedle patch. This innovative approach enhances immune response and offers a minimally invasive delivery method for lymphoma immunotherapy.
Area of Science:
- Biomedical Engineering
- Immunology
- Materials Science
Background:
- Tumor whole-cell vaccines are crucial for introducing diverse tumor antigens to combat tumor-induced immunosuppression, especially for lymphomas with undetermined specific antigens.
- Current preparation methods for lymphoma whole-cell vaccines are underdeveloped, hindering their clinical application.
- Direct injection of whole-cell vaccines often leads to low delivery efficiency and poor patient compliance.
Purpose of the Study:
- To develop an effective preparation method for a lymphoma whole-cell vaccine.
- To create a novel delivery system for enhanced vaccine efficacy and patient adherence.
- To investigate the immunogenic potential of the prepared whole-cell vaccine.
Main Methods:
- Preparation of a whole-cell vaccine from non-Hodgkin B-cell lymphoma (A20) using Prussian blue nanoparticles (PBNPs) and photothermal effects.
- Induction of immunogenic cell death (ICD) in A20 cells via PBNPs, followed by ultrasonic crushing to create the vaccine.
- Development of a porous microneedle patch system using Gelatin Methacryloyl (GelMA) and n-arm-poly(lactic-co-glycolic acid) (n-arm-PLGA) for vaccine delivery.
Main Results:
- PBNPs induced ICD in A20 cells, preserving immunogenicity while eliminating tumor-forming ability.
- The prepared A20 whole-cell vaccine effectively activated dendritic cells (DCs) and T cells, triggering specific anti-lymphoma immune responses.
- The GelMA/n-arm-PLGA microneedle patch system facilitated efficient intradermal vaccine delivery, improving lymphatic absorption and patient compliance.
Conclusions:
- The PBNPs-mediated photothermal effect provides an effective method for preparing immunogenic lymphoma whole-cell vaccines.
- The developed microneedle patch system offers a promising, minimally invasive approach for whole-cell vaccine delivery.
- This combined strategy represents a significant advancement in lymphoma immunotherapy, with potential for controllable production and improved patient outcomes.
More Related Videos
08:15In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D
Published on: December 9, 2022
07:32Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
Published on: September 1, 2023
Related Concept Videos
01:51Vaccinations
01:23Vaccine Production